Skip to main content
. 2017 Feb 24;49(1):22–30. doi: 10.3947/ic.2017.49.1.22

Table 6. Clinical characteristics of the CA-APN patients with structural abnormalities.

Clinical Characteristics With Structural abnormalities
N = 81
n (%)
Without Structural abnormalities
N = 602
n (%)
P-value
Age≥70 years 28 (34.6) 171 (28.4) 0.252
Underlying conditions
 Charlson co-morbidity index ≥1 33 (40.7) 248 (41.2) 0.938
 Diabetes mellitus 17 (21.0) 174 (28.9) 0.136
 Cerebrovascular disorder 10 (12.3) 54 (9.0) 0.328
 Congestive heart failure 2 (2.5) 36 (6.0) 0.299
 Dementia 6 (7.4) 18 (3.0) 0.054
 Chronic pulmonary disease 1 (1.2) 16 (2.7) 0.708
 Chronic liver disease 2 (2.5) 19 (3.2) 1.000
 Chronic bed ridden state 3 (3.7) 23 (3.8) 1.000
Past history
 History of urinary tract infection within 1 year 23/68 (33.8) 147/526 (27.9) 0.313
 History of admission within 1 year 24/73 (32.9) 131/548 (23.9) 0.096
 History antibiotics use within 1 year 24/59 (40.7) 163/494 (33.0) 0.238
Clinical findings
 Pitt score ≥1a 42 (51.9) 191 (31.7) <0.001
 Costovertebral angle tenderness 58 (71.6) 393 (65.3) 0.259
 Flank pain 33 (40.7) 179 (29.7) 0.044
 Lower urinary tract infection symptoms 49 (60.5) 389 (64.6) 0.468
Laboratory findings
 Hematuria (urine RBC > 5~9/HPF) 51 (63.0) 314 (52.2) 0.067
 Azotemiab 25 (30.9) 88 (14.6) <0.001
 WBC >20,000/mm3 11 (13.6) 61 (10.1) 0.343
 CRP >20 mg/dl 23 (28.4) 173 (28.7) 0.949
Clinical outcomes
 Duration of hospitalization (days, mean ± SD) 11.5 ± 6.7 8.8 ± 5.8 <0.001
 Defervescence time (days, mean ±SD) 3.5 ± 3.2 2.5 ± 2.3 0.001
 Hospital mortality 3 (4.2) 8 (1.4) 0.119
 Final clinical failure 6 (8.5) 25 (4.5) 0.150

aSee method for calculation of Pitt score

bAzotemia was defined as serum BUN ≥ 20 mg/dL and/or serum creatinine ≥ 2.0 mg/dL.

CA-APN, community-acquired acute pyelonephritis; RBC, red blood cell; HPF, high-power field; WBC, white blood cell; CRP, C-reactive protein; SD, standard deviation; BUN, blood urea nitrogen.